GU Cancers 2020 | CaboPoint: second-line cabozantinib for RCC

Name: CaboPoint: second-line cabozantinib for RCC
Uploaded: 2020-02-15T18:11:07Z
Description: Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as a second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Laurence Albiges • 15 Feb 2020

GU Cancers 2020

Genitourinary Cancer Kidney Cancer Antibodies Cabozantinib Ipilimumab Nivolumab

CaboPoint

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as a second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.